Licui Jiang

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

Fengtao You, Licui Jiang, Bozhen Zhang et al. · Science China Life Sciences · 2016 · 148 citations · Full text

A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.

Fengtao You, Yinyan Wang, Licui Jiang et al. · PubMed · 2019 · 130 citations · Full text

Immunology, Immunoediting, Immunodominance +19

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody

Ying Chen, Fengtao You, Licui Jiang et al. · Oncotarget · 2017 · 49 citations · Full text

Cancer-killing Ability, Tumor Immunology, Nk-92mi Cells +15

MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.

Xiaochen Zhai, Fengtao You, Shufen Xiang et al. · PubMed · 2021 · 27 citations · Full text

Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia

Tingting Zhang, Tian Wang, Fengtao You et al. · Transplant Immunology · 2022 · 15 citations · Full text

Chimeric Antigen Receptor, Cell Therapy, Cancer Immunosurveillance +13